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DECLARACIÓN DE CHINCHÓN; DECÁLOGO
SOBRE EDULCORANTES SIN Y BAJOS
EN CALORÍAS (ESBC)
Resumen
Expertos de carácter multidisciplinar de las áreas de
conocimiento de la nutrición y la salud reunidos en Chin-
chón, Madrid, los días 25 y 26 de noviembre de 2013 , bajo
los auspicios de la Fundación para la Investigación Nutri-
cional y con la colaboración de la Consejería de Sanidad
del Gobierno de la Comunidad de Madrid, la International
Sweeteners Association y el CIBER de Fisiopatología de la
Obesidad y la Nutrición del Instituto de Salud Carlos III,
analizaron el estado actual del conocimiento científico en
torno a los Edulcorantes sin y bajos en calorías (ESBC) y
desarrollaron un Decálogo sobre su uso que constituye la
Declaración de Chinchón. Los edulcorantes, incluido el
azúcar, constituyen un elemento de indudable interés y
actualidad, aunque no exento de desconocimiento por
algunos sectores tanto académicos como de la población en
general. La propia naturaleza de los ESBC los hace suscep-
tibles de informaciones tergiversadas e incluso contradic-
torias. Son aditivos alimentarios ampliamente utilizados
como sustitutivos del azúcar para endulzar alimentos,
medicamentos y complementos alimenticios cuando se
persiguen fines no nutritivos. El Decálogo de Chinchón es
fruto de una reunión de reflexión y consenso por parte de
Abstract
Multidisciplinary experts in the areas of nutrition and
health met in Chinchón, Madrid, on November 25-26, 2013
under the auspices of the Fundación para la Investigación
Nutricional (Nutrition Research Foundation) and with the
collaboration of the Madrid Regional Government’s Health
Ministry, the International Sweeteners Association and the
Carlos III Health Institute CIBER of Physiopathology of
Obesity and Nutrition. They analyzed the current status
of scientific knowledge on low- and no-calorie sweeteners
(LNCS) and developed a consensus Decalogue on their use;
this constitutes the Chinchón Declaration. Sweeteners,
including sugar, represent a subject of undeniable
interest and are currently a popular topic, although areas
relating to their safety and benefits remain unknown to
segments of academia and the general public. The nature
of LNCS makes them vulnerable to biased and even
contradictory information. They are food additives that
are broadly used as sugar substitutes to sweeten foods,
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medicines and food supplements when non-nutritional or
non-caloric alternatives are needed. The Chinchón
Decalogue is the outcome of a meeting for reflection and
consensus by a group of experts with backgrounds in
different scientific disciplines (toxicology, clinical nutrition,
community nutrition, physiology, food science, public
health, pediatrics, endocrinology and nutrition, nursing,
pharmaceutical care and food legislation). The Decalogue
includes different aspects of LNCS related to regulation,
use, benefits and safety. In general, benefits of LNCS have
been traditionally neglected in comparison with the
tendency for emphasising unexisting or unproven possible
risks. The need to strengthen research on LNCS in Spain
was emphasized, as well as the need to educate both
professionals and the public.
(Nutr Hosp. 2014;29:719-734)
DOI:10.3305/nh.2014.29.4.7393
Keywords: Low-calorie sweeteners. Non nutritive sweete-
ners. Safety. Benefits. Consensus.
un grupo de expertos procedentes de distintas disciplinas
científicas (toxicología, nutrición clínica, nutrición comu-
nitaria, fisiología, bromatología, salud pública, atención
primaria, pediatría, endocrinología y nutrición, enferme-
ría, atención farmacéutica y legislación alimentaria). El
decálogo incluye diferentes aspectos de los EBSC relacio-
nados con la legislación, uso, beneficios y seguridad. En
general, los beneficios de los EBSC han sido tradicional-
mente desatendidos en comparación con la tendencia de
destacar posibles riesgos inexistentes o que no han sido
probados. Hace especial hincapié en la necesidad de forta-
lecer la investigación de los EBSC en España, así como la
necesidad de formar en este ámbito a los profesionales y a
los consumidores en general.
(Nutr Hosp. 2014;29:719-734)
DOI:10.3305/nh.2014.29.4.7393
Palabras clave: Edulcorantes bajos en calorías. Edulco-
rantes no nutritivos. Seguridad. Beneficios. Consenso.
Multidisciplinary experts in the areas of nutrition and
health met in Chinchón, Madrid, on November 25-26,
2013 under the auspices of the Fundación para la Investi-
gación Nutricional (Nutrition Research Foundation) and
with the collaboration of the Madrid Regional Govern-
ment’s Health Ministry, the International Sweeteners
Association and the Carlos III Health Institute CIBER of
Physiopathology of Obesity and Nutrition. They
analyzed the current status of scientific knowledge on
low- and no-calorie sweeteners (LNCS) and developed a
consensus Decalogue on their use; this constitutes the
Chinchón Declaration. Sweeteners, including sugar,
represent a subject of undeniable interest and are
currently a popular topic, although areas relating to their
safety and benefits remain unknown to segments of
academia and the general public. The nature of LNCS
makes them vulnerable to biased and even contradictory
information. They are food additives that are broadly
used as sugar substitutes to sweeten foods, medicines
and food supplements when non-nutritional or non-
caloric alternatives are needed. The Chinchón Deca-
logue is the outcome of a meeting for reflection and
consensus by a group of experts with backgrounds in
different scientific disciplines (toxicology, clinical nutri-
tion, community nutrition, physiology, food science
public health, pediatrics, endocrinology and nutrition,
nursing, pharmaceutical care and food legislation). It
comprises the following points:
1. LNCS have been used safely by consumers
throughout the world for more than a century. In
Europe there are ten different authorized LNCS:
acesulfame K (E-950), aspartame (E-951), cyclamate
(E-952), saccharine (E-954), thaumatine (E-957),
neohesperidine DC (E-959), steviol glycosides (E-
960), neotame (E-961) and salts of aspartame and
acesulfame (E-962). There are also other kinds of low-
calorie sweeteners authorized, such as the polyalcohols
(sorbitol: E-420, xylitol: E-967) which are widely used
in food products. The description and declaration of all
these ingredients on product labeling is mandatory, just
as it is for all other additives.
2. All of the no-calorie and low-calorie sweeteners
currently used have been subjected to strict safety
tests. The LNCS regulatory process is scrupulous and
obtaining authorization for a new LNCS is a long and
highly scientifically robust procedure; sometimes it
can take up to 20 years. All additives have an estab-
lished Acceptable Daily Intake (ADI) that represents
a quantity guideline for health safety purposes. These
ADI levels are established by international regulatory
bodies [Joint FAO/WHO Expert Committee on Food
Additives (JECFA), the European Food Safety
Authority (EFSA) and the U.S. Food and Drug
Administration (FDA) among others]. They define
the ADI as the measurement of the amount of an
authorized additive that can be consumed in a
person’s daily diet (food or drink) over an entire life-
time without any appreciable risk to health.
3. Current scientific evidence indicates that there
is no relationship between the consumption of LNCS
and the appearance of non-communicable diseases.
Very recent studies done with humans have analyzed
the possible epidemiological relationship between the
consumption of LNCS and different kinds of cancer,
without finding any type of relationship or trend.
Their consumption was not linked to cardiovascular
disease, neurological diseases or with any alterations
or effects related to pregnancy. Therefore, their
consumption within the quantities indicated, repre-
sents no health risk in light of existing scientific
evidence. 
4. Scientific evidence shows that LNCS do not
affect glucose or insulin levels in blood plasma. There-
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The sweet taste across the life stages
Gregorio Varela-Moreiras
Very few of our taste preferences are biologically
present. In fact they are linked with some sort of
experience. Although there are some genetic factors
that cause differences in taste perception, similari-
ties in taste preferences much more commonly
reflect similar experiences with types of flavours
and foods. The shaping of taste preferences begins
in the womb and continues throughout the rest of
our lives.
The sensory system is pretty much complete by the
time of birth. Taste buds mature by the last trimester of
pregnancy. Newly-born babies react to sweet, sour, and
bitter tastes - but not so much to salt. It is also believed
that prenatal exposure to food odours, derived from
foods consumed by the mother in the course of preg-
nancy, can influence future food preferences and eating
habits.
Babies like sweet and dislike bitter tastes. This can in
fact be noted from their facial expressions. A drop of a
sweet tasting substance on the tongue makes the infant
smile and relaxes. Taste preferences for sweetness are
maximal in infancy and childhood and progressively
drop during adolescence and adult life. Children adore
foods that would be much too sweet for adults. So the
basic liking for sweetness is an innate human trait. The
preferred level of sweetness is determined first by age
and only thereafter by culture. On the other hand,
humans equate bitter taste with dietary danger.
fore, LNCS represent an additional instrument in the
dietary treatment of people with diabetes and obesity
and constitute a key element in carbohydrate metabolic
control.
5. Scientific research shows that the consumption of
foods and drinks in which sugar has been replaced by
no-calorie and low-calorie sweeteners combined with
physical activity and a healthy lifestyle can play a
significant role in weight loss and the maintenance of a
healthy weight. Therefore, this is a helpful tool in the
prevention of overweight and obesity and of weight
management in general. Scientific studies have shown
that people who use low and no calorie sweeteners in
their diets consume fewer calories than those who have
diets with the equivalent caloric products. They also
show better energy balance.
6. However, in the face of the uncertainty that is
sometimes generated about the impact of LNCS
consumption on the eating habits and physical
activity of people who consume them, nutrition
education and a healthy lifestyle need to be strength-
ened, with particular emphasis on the promotion of
physical activity and exercise. In childhood the use of
these types of additives should only be considered as
an alternative resource when other preventive strate-
gies have failed, with the exception of the use of
chewing gum to prevent tooth decay as well as use in
pharmaceutical products.
7. Moreover, LNCS help prevent cavities. In Spain,
in barely 20 years, the incidence of dental cavities at 12
years of age has been reduced by 50%. This has
demonstrated that factors such as hygienic and dietary
measures, surface and systemic fluoride treatments and
the use of low- and no-calorie sweeteners that are non-
cariogenic (or are even cariostatic, reducing the inci-
dence of cavities) —such as xylitol— have been deci-
sive in this public health success. This could represent
a complementary model for the control of other chronic
diseases in the future.
8. Consumer education about these products must
be strengthened in a rigorous, objective way, based on
the best scientific evidence and regulatory processes.
Responsible administrations and scientific societies
should disseminate clear, objective information about
LNCS on their websites and social networks, and
publish educational materials that contribute to the
dismissal of doubts and any misinformation that may
exist. In this process, the food and pharmaceutical
industries should share the information about the
content of the sweeteners in their products, for infor-
mational and investigative purposes. All of this should
reinforce the effort that governments, food safety agen-
cies, professionals and scientists have been making to
communicate and strengthen consumers’ trust and
responsibility with regard to these products.
9. Training provided to primary care and speciali zed
healthcare professionals, dentists and pharmacists should
be made a priority in order to make them educational
agents on these types of products among the healthy popu-
lation and in groups with special needs. The training of
educators and teachers in primary and secondary schools
should also be considered, as well as professionals in
general who are linked to diet, nutrition and health.
10. The need to strengthen research on LNCS in
Spain was emphasized, to incentivize the monitoring of
LNCS intake levels in different population groups and
facilitate the execution of multidisciplinary projects on
the subject. This is equally applicable to other additives
or ingredients or substances present in food products,
through Total Diet studies or other methods. Research,
in addition to being an engine for knowledge and
science, constitutes a fundamental element for training
healthcare professionals and for the public’s health
information and education.
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Prenatal shaping
Human senses are established in the embryonic
phase (weeks 1-8 of gestation) and at the start of the
foetal phase, and mature at varying rates. The sense of
taste also, forms and matures at an early stage (the first
taste buds appear at eight weeks of gestation). Aroma
compounds in the amniotic fluid stimulate the foetal
taste receptors as soon as the foetus starts swallowing
(around 12th week of gestation).
Amniotic fluid composition changes along with the
development of the foetus. Flavours from the maternal diet
reach the amniotic fluid. For newborns, the sense of taste is
the most important and most developed of all senses.
Breast milk shapes preferences
Human breast milk contains numerous aroma
compounds that the mother acquires through her diet.
The taste of breast milk may impact on the later prefer-
ences of the newborn. Children often like foods they
have eaten in pleasant situations and reject dishes
linked to something negative.
Infancy
The neophobia effect protects infants from eating
harmful or poisonous foods. At an age when children
start walking and become more independent in
choosing their foods, neophobia may have a certain
survival value. Older children and adults possess
successful means to overcome their innate neophobia.
Although the rejection of new foods appears innate,
there are individual and gender-specific differences to
neophobia, with women seemingly less affected than
men. Furthermore, similarities within families hint at a
genetic component.
Teenagers
Older children strive to emulate adults, and will
force themselves to ingest things they dislike the taste
of, regardless of the flavour. Interestingly, hormones
play a key role in how we experience food. Therefore,
it has been shown that girls are more sensitive to sweet
and sour tastes than boys.
Ageing
Loss of the sense of taste is common among older
people (usually starting at 40 to 50 years in women
and 50 in men), but the cause of taste loss is not fully
understood. Theories include a decline in gustatory
function due to physiological decline in the density of
the taste buds and papillae. Alteration in the sense of
taste may be due to various central (involvement of
the “Taste area” in the temporal lobe) or peripheral
(changes in the receptor cell taste buds) functions.
Bitter taste is the first to be affected and is the last to
be recovered while sweetness is affected later and is
the first to be regained. However, true gustatory
disorders are rare.
In addition to physiological changes associated with
the ageing process, the most common causes of taste
disorders are: oral and systemic diseases (7.4 and 6.4%,
respectively), drug use (21.7%) and zinc deficiency
(14.5%). The main consequence of taste decline and
disturbance in the elderly is food-anhedonia (inability to
experience pleasure), causing loss of body weight via
decreased calorie and nutrient intake. And of course, any
change in nutrient intake can lead to malnutrition with its
potentially serious consequences. When considering
prevention and/or treatment, it is recommended to
administrate zinc and/or iron. However the suggestion to
use food enhancers or flavours would be appropriate so
as to improve dietary intake.
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History, types of caloric and non caloric sweeteners and intake
Javier Aranceta Bartrina
From the beginning of time there is evidence of the
use of sweeteners as nutritious substances and also
with a role as gourmet facilitators for the culinary
preparation of certain foods. As such, these compo-
nents are used as preservatives, texturizers and other
uses related to the preservation and improvement of the
organoleptic qualities of food.
Sweet taste seems to have the most pleasant impact
on humankind, possibly as a genetically encoded pecu-
liarity and a survival mechanism. The first food, breast
milk, produces the first sensation of sweetness and
wellbeing. It is a perception of comfort that can induce
a smile in newborns universally.
The term Sweetener is given to any natural or artifi-
cial sweetening substance used to provide sweetness to
a food or product that would be otherwise bitter,
unpleasant or tasteless.
Sweetening, a historical view
Classical natural sweeteners have also been termed
sweeteners. Initially humans used the manna tree,
honey or a variety of concentrated grapes such as
defrutum or arrope for this purpose.
In classical times apart from these products, the
first artificial sweetener used was lead acetate, also
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known as “lead sugar”. This substance was utilised
both in common recipes and elite cookery books of
the time as described in Apicus, a Roman cookbook
dated in the late fourth century. An average Roman
could have about 20 mg of lead per day with wine and
other foods.
Sugar cane has been known since 3,000 years before
Christ, mainly as an ornamental use. The use of sugar
cane in cookery started by the time of King Darius. He
referred to it as “this cane that gives honey without
bees.”
The Crusaders introduced sugar cane to Europe.
They found sugar cane plantations in the Arab territo-
ries and the plains of Tripoli. Since then, sugar was
introduced into Europe, although initially the most
common utilisation was limited to use as a drug in
pharmacies.
Finally, the Arabs introduced sugar cane culture and
the unique use of sugar in gastronomy, especially in
pastries as they progressed throughout the Mediter-
ranean basin. Many of these culinary formulas rich in
honey, sugar and nuts persist to date across the Spanish
geography, in the Maghreb and in other locations.
From its presence in the Iberian Peninsula, sugar
cane was also introduced to the islands, such as the
Canary Islands, Madeira and the Azores. In 1493
Christopher Columbus brought sugar cane to the
Americas. 
Traditionally sugar has facilitated the widespread
consumption of coffee, tea, pastries and a large number
of foods and drinks.
The extraction of sugar from the sugar beet can be
attributed to the German scientist Andreas Marggraf,
who in 1747 showed that the crystals obtained from
beet juice were equivalent to those of sugar cane.
During the Napoleonic wars and the British blockade
of the French commercial lines in 1811, Napoleon
ordered the planting of 32,000 hectares of beets as a
supply for the empire. Due to this decision, today
almost 90% of the sugar consumed in Europe is
obtained from beets. The first sugar beet processing
factory was built in Cunern, in Lower Silesia in 1801.
This calm and peaceful relationship with classical
sweeteners, especially sugar, was disturbed in the first
half of the twentieth century, when a negative role was
attributed to sugar in relation to health, viewed as a
potential inductor of certain diseases such as diabetes,
cardiovascular diseases, dyslipidemia, etc.
This perspective encouraged research driving the
development of sweetening products that provide
fewer calories, or even zero calories, enabling its use in
population groups that need energy restriction or
limited glucose intake.
In general, no-calorie and low-calorie sweeteners
are used as sugar substitutes in the preparation of a) low
calorie foods and drinks, b) non-cariogenic products, c)
no sugar added foods that enable better preservation;
and d) products for weight control, for diabetic patients
or people with reactive hypoglycaemia.
Artificial sweeteners
Saccharin. Known as the oldest artificial sweetener,
it is 300 times sweeter than sucrose but has a distinct
metallic aftertaste. It was discovered by chance in 1879
by Constantin Fahlberg and Ira Remsem at Johns
Hopkins University while doing tests on toluene oxida-
tion. The first commercial use started in 1901 as a soda
sweetener and was approved for use in more than 90
countries.
Cyclamate. These are sodium and calcium salts of
cyclohexyl sulfamic acid having a sweetener potential
30 times stronger than sucrose (E-952). It was discov-
ered in 1937 at the University of Illinois. The European
Food Safety Authority (EFSA) supports its use.
Aspartame. It was synthesized by Schlatter in 1965
within a research program on peptides for pharmaceu-
tical use. It is formed by the amino acids aspartic acid
and phenylalanine in the form of methyl ester. The
FDA authorized its use in 1983. It is 200 times sweeter
than sucrose, resists heat poorly and is not suitable for
people with phenylketonuria. A new report from EFSA
showed a favourable evaluation in 2013.
Acesulfame K. A sweetener discovered in 1967. It is
heat stable and well suited for combining with other
sweeteners, enhancing the perception of flavour and
freshness. It is not metabolized in the body and
contains no sodium. Approved by the FDA and EFSA.
Sucralose. Semisynthetic sweetener obtained in
1976 by Tate & Lyle with L. Hough and S. Phadnis at
Queen Elizabeth College, London. It is about 400 times
sweeter than sucrose, calorie-free, water-soluble and
heat stable. It was approved for use in the EU in 2004.
Advantame is a new sweetener and flavour enhancer
developed by Ajinomoto. It is derived from aspartame
and vanillin and is much more potent than aspartame. It
is licensed in Australia and New Zealand. In 2013
EFSA declared it as a safe sweetener.
Non-caloric natural sweeteners
Steviosides. These are substances from herbs and
shrubs from the sunflower family (Asteraceae) origi-
nating in South America, Central America and Mexico.
They were studied first by the Spanish botanist and
physician Petrus Jacobus Stevus (1500-1556). The so-
called “sweet herb” (Stevia rebaudiana) has been used
in Paraguay since pre-Columbian times to sweeten
mate and confectionery. The leaves are 10 to 15 times
sweeter than sugar and stevioside and rebaudioside’s
sweetness are about 300 fold that of sugar. The use of
these substances was approved in the U.S. in 2008 and
in the EU in late 2011.
Luo Han Guo. Fruit used in Chinese popular medi-
cine obtained from a perennial plant from the Cucur-
bitacea plant family (Grosvenoril Siraitia). Its sweet-
ening extract is heat stable, non-fermented and doesn’t
alter any organoleptic properties of the food.
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Thaumatins. Belongs to a group called sweet
proteins. It is extracted from the fruit of Thaumato-
coccus Danielli that grows in West Africa. Its sweet-
ening property was documented by WF Daniell in
1855. It is now used to sweeten and flavour foods and
drinks. Thaumatin has a sweetening power 3000 times
higher than sugar.
Monatin. Also known as ajinomoto, this is a second-
generation natural sweetener, 1400 times sweeter than
sugar. It is extracted from the root bark of Schlero-
chiton Ilicifolius, a native plant from northern Trans-
vaal in South Africa. 
Importantly, there is significant use of low calorie
sweeteners such as polyhydric alcohols, sorbitol,
mannitol, lactitol, maltitol and xylitol. Along with
tagatose and trehalose these are the main natural low-
calorie sweeteners.
Other sweetening substances: There are many often
used substances with sweetening potential, such as hydro-
genated starch hydrolysate, fructose, coconut sugar,
dehydrated date sugar, brown sugar, honey, agave syrup,
maple syrup, molasses from rice, barley, corn, wheat, a
number of berries or some fruits like apple syrup.
In the field of sweet taste, it is important to find
available sweetness enhancing substances and other
components able to modulate flavours of natural or
synthetic sweeteners. The Redpoint Bio and Senomyx
are examples of such components that allow reducing
by up to 50% the amount of caloric sweetener added
or enhancing the sweet taste of stevia or high fructose
corn.
Consumption of sugar and sweeteners
According to data published in 2013 by Mercasa,
globally some 213,800 thousand tons of sugar beet,
1,339,000 thousand tons of sugar cane and 174,468
thousand tons of refined sugar were produced. In
Spain in 2012 the estimated consumption was 189.3
million kilos which represents a per capita consump-
tion of 4.1 kg per year, being lower than the European
average. The total estimated consumption of sweet-
eners is 0.1 kg/per capita/per year. The highest
consumption of sugar is detected in La Rioja, Asturias
and Galicia and the lowest in Navarra, Castilla La
Mancha and Madrid. The individual typology of
higher sugar consumption is embodied with more
intensity in older, retired people living alone and in
those with low income levels.
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Low- and no-calorie sweeteners; aspects on safety
Arturo Anadón Navarro
European legislation on food 
additive sweeteners
Harmonized legislation on sweeteners in foodstuffs
was adopted in the European Union (EU) in 1994
[European Parliament and Council Directive 94/35/EC
of 30 June 1994 on sweeteners for use in foodstuffs (OJ
L 237, 10.9.1994)]; the annex of this Directive indi-
cates the maximum usage levels of each LNCS in a
given food category.
Subsequently, the Regulation (EC) No 1333/2008 of
the European Parliament and of the Council of 16
December 2008 on food additives (OJ L 354/16;
31.12.2008) requires that food additives are subject to a
safety evaluation by the European Food Safety
Authority (EFSA) before they are permitted for use in
the EU. In addition, it is foreseen that food additives
must be kept under continuous observation and must be
re-evaluated by EFSA. For this purpose, a programme
for the re-evaluation of food additives that were already
permitted in the EU before 20 January 2009 has been set
up under Council Regulation (EU) No 257/2010 of 25
March 2010 (OJ L 80/19; 26.3.2010). The re-evaluation
of all sweeteners is foreseen to be completed by the end
of 2020. However, in 2011 the deadline for the re-evalu-
ation of aspartame was moved forward to May 2013 in
light of new scientific information.
All LNCS are subject to comprehensive safety evalua-
tion by regulatory authorities, prior to approval. Scientists
evaluate these sweeteners for many attributes including
sensory qualities (eg, clean sweet taste, no bitterness,
odourless), safety, compatibility with other food ingredi-
ents, and stability in different food environments.
Safety testing of food additive sweeteners
The safety testing of food additive sweeteners
requires studies in laboratory animals to determine
what effects the compound is capable of producing
when administered at high daily doses, or high dietary
concentrations. Very high dose levels are used to
increase the ability of the study to detect any possible
adverse effects. 
Table I shows routine procedures for testing the
safety of food additives.
For sweeteners, this testing may be expanded to
address specific end-points (eg, neurotoxicity and
immunotoxicity testings) and effects on humans with
relevant conditions (eg, testing sweetener effects on
glucose homeostasis in those with diabetes). The neuro-
toxicity and immunotoxicity responses are based on
short-term and subchronic toxicity studies. The previous
tests establishes a safety limit of food additive sweet-
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eners or conditions of use that are expressed as human
intake with negligible risk (or as the estimated amount
that a person can safely consume on average every day
over a lifetime without risk), which is called the accept-
able daily intake (ADI). 
Use levels are set to assure that intakes are below the
ADI. The regulatory bodies Joint FAO/WHO Expert
Committee on Food Additives (JECFA), Scientific
Committee on Food (SCF) and European Food Safety
Authority (EFSA) monitor estimated daily intakes
(EDI) versus ADI. If EDI exceed the ADI, there may be
limitations on use of the sweetener. 
The ADI for a sweetener is not intended to define the
maximum dose that would be safe to consume on any
given day; it is a guideline for quantity levels, and
therefore it is implicit that a person may occasionally
consume a sweetener in quantities in excess of the ADI
value without adverse effects on health. For instance,
there is evidence that children’s intake of LNCS is
greater than adult consumption, in particular in chil-
dren with diabetes; however there is no risk for
exceeding the ADI values. 
The ADI is usually calculated as the NOEL/NOAEL
(in mg/kg bw/day) divided by an uncertainty (safety)
factor of 100, which is to allow for possible species
differences and human variability. 
Metabolism data are usually available from studies
in humans to support extrapolation of toxicity data
from the test animal species to humans. Any human
study would have to fulfil criteria of adequate duration,
group size, group composition, daily dosage and also
investigate the endpoints detected in rats at intake
above the NOEL/NOAEL. 
Health-based guidance values for sweeteners
Derivation of a health-based guidance value such as
an ADI for food additive sweeteners that produce
adverse effects uses information on dose-response rela-
tionships. At the risk characterization stage, comparison
of the exposure assessment with the health-based guid-
ance values may indicate that additional dose-response
assessment may be necessary for the formulation of
advice to risk managers. The objective of hazard charac-
terization is to determine the relationship that exists
between the magnitude of exposure to a sweetener agent
and the severity and/or frequency of associated adverse
health effect in experimental animals. This is defined as
the dose-response relationship. The dose-response rela-
tionship must be established for each toxicological
endpoint in each study and aids in the determination of a
NOAEL for a particular endpoint in the study. The
lowest NOAEL in a study is the study NOAEL. The
lowest NOAEL amongst all of the endpoints in all of the
studies is often referred to as the critical NOAEL.
Health-based guidance values for compounds that are
both genotoxic and carcinogenic have not been estab-
lished using the NOAEL. 
There is no appreciable risk at intakes below the
health-based guidance value. The critical risk assess-
ment issue that should be considered in recommending
different health-based guidance values for different
population subgroups is whether the most sensitive
critical health outcome is irrelevant for a significant
part of the whole population. The numerical result of
this estimation, the EDI, is then compared with the type
and amount of additive residue considered to be
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Table I
Toxicology testing for food additives
Toxicity test Outputs
Acute toxicity (single dose) (to define extent of toxicity in absence Nature of acute effects (overdose); median lethal dose. 
of other data)
Subacute/subchronic toxicity (28-90 days); usually two species Suitable dose levels for chronic toxicity studies; nature of toxicity;
(rodent and non-rodent) target organ(s); dose-response; NOEL (no-observed-effect level);
NOAEL (no-observed-adverse effect level); maximum tolerated dose. 
Mutagenicity/Clastogenicity (Short-term tests for capacity to interact Evidence of potential genotoxicity. 
with DNA and to cause mutations or chromosome changes using a 
variety of end-points in bacterial and mammalian systems, in vitro
and in vivo).
Chronic toxicity (long-term dietary administration, eg, 6 months to Nature of chronic toxicity; target organ(s); cumulative effects; 
2 years); provide the data most frequentely used in deriving the ADI. dose-response characteristics; NOEL /NOAEL.
Carcinogenicity (long-term administration at maximum tolerated dose). Carcinogenic potential
Reproductive toxicity (single/multiple dose studies during pregnancy; Effects on male and female fertility; fetotoxicity; teratogenic potential; 
multigenerational studies with dietary administration prior to and during effects on lactation and post-natal development.
mating, gestation, and suckling); usually involves a multigeneration 
study in a rodent and developmental toxicity in two species.
Metabolism and pharmacokinetic studies Degree of absorption, distribution in the body, route of metabolism and
metabolites, degree and mode of elimination.
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without toxicological hazard for human health, as
expressed by the ADI. 
The ADI values for the LNCS sweeteners currently
approved for use in the EU are expressed in table II.
The use of the ADI principle for toxicological evalu-
ation and safety assessment of food additive sweet-
eners is accepted worldwide by all regulatory bodies.
The E number for LNCS sweeteners assures that they
have passed stringent safety tests and are approved for
use throughout the EU. In the EU the label on food-
stuffs containing sweeteners must state its presence,
indicating either its name or its E number.
Low- and No-Calorie Sweeteners (LNCS)
Extensive scientific research has demonstrated the
safety of the LNCS (table II). The safety assessment for
aspartame, cyclamate and stevia/steviol glycosides are
described.
Aspartame
Aspartame is a low-calorie, intense artificial food
additive sweetener authorized in the EU. It is a white,
odourless power. The aspartame molecule consists of
two amino acids, phenylalanine and aspartic acid,
linked to methanol. Methanol also occurs naturally in
foods and is produced by the digestion of other food
constituents. Aspartame itself does not occur naturally.
Intestinal esterases hydrolyze aspartame rapidly and
completely in the gastrointestinal tract to methanol and
the amino acids phenylalanine and aspartic acid.
At a worldwide level the Joint FAO/WHO Expert
Committee on Food Additives (JECFA) and at the EU
level the Scientific Committee on Food (SCF) delivered
several scientific opinions. The first SCF safety assess-
ment was in 1984 and subsequent complementary assess-
ments in 1988, 1997 and 2002. The SCF task was followed
from 2003 by the European Food Safety Authority
(EFSA) which performed different scientific opinions on
the safety of aspartame (E 951). The JECFA (1975, 1980)
and SCF committees established an ADI of 0-40 mg/kg
bw/day based on chronic toxicity and carcinogenicity
studies in rats and applying an uncertainty factor of 100.
The available data do not indicate a genotoxic concern for
aspartame. The chronic toxicity, reproductive and devel-
opmental toxicity, and neurotoxicity were the critical
endpoints in the animal database but however it is
possible to conclude aspartame is not a carcinogen and it
is not associated with reproductive/development and
neurobehavioral disorders.
The possibility of developmental toxicity occurring
at lower doses than 4000 mg/kg in animals could not be
excluded. Based on mode of action (MoA) and weight-
of-evidence analysis, the EFSA ANS Panel concluded
that developmental toxicity in animals was attributable
to phenylalanine. Phenylalanine at high plasma levels
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Table II
Low- and no-calorie sweeteners used in Europe
Caloric Potency ADISweetener
value (times sweeter Stability Uses (for childrenthan sucrose) and adults)
Acesulfame K (E950) 00 200 Heat stable, suitable Drinks, foods, table-top 0-9 mg/kg 
K (E950) for cooking and baking sweeteners, oral-care and 
pharmaceutical products
Aspartame (E951) 4 kcal/g 200 Looses sweetening properties Drinks, desserts, sweets, dairy, 0-40 mg/kg 
when exposed to high temperature chewing gums, energy-reducing 
(not recommended for baking; and weight control products and 
can be added to foods at the end as a table-top sweetener. It is not 
of cooking cycle) stable if subjected to prolonged 
heating, and cannot be used in 
baking or cooking
Cyclamate (E952) Calorie free 30 Good stability at high and low Table-top sweeteners, drinks, 0-7 mg/kg 
temperatures; can be used in chewing gums, salad dressings 
cooking and baking; good solubility. and jams
Saccharin (E954) Calorie free 300 Heat stable, can be used in Table-top sweeteners, drinks, 0-5 mg/kg
cooking and baking desserts and confectionery
Sucralose (E955) Calorie free 300 Good stability at very high Baked goods, desserts, 0-15 mg/kg 
temperatures; can be used in ice-cream and dairy
cooking and baking. products, breakfast cereals,
Good solubility. and confectionery
Steviol glycoside Calorie free 250-300 Heat stable. Drinks, desserts, yogurts, 0-4 mg/kg 
(E960) confectionary, cakes, biscuits (expr. steviol)
and pastries, sauces, toppings,
spread, cereals, canned fruits,
and jams among others.
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is known to cause developmental toxicity in humans.
In addition, EFSA concludes that aspartame and its
breakdown products (i.e. phenylalanine, aspartic acid
and methanol) pose no safety concern for consumers at
current levels of exposure. The current ADI is consid-
ered to be safe for the general population and consumer
exposure to aspartame is below this ADI. This ADI is
not applicable to people who suffer from the hereditary
disease phenylketonuria (ie, a homozygous recessive
inborn error of metabolism of which affected individ-
uals cannot metabolize phenylalanine), who must
strictly limit their intake of phenylalanine. In the EU all
products (foods and beverages) containing aspartame
must place a statement on the label indicating that the
product “contains a source of phenylalanine”.
Cyclamate
Cyclamate was discovered in 1937. It was used as a
low-calorie sweetener in the United States in the 1950s
and 1960s. Cyclamate was extensively used during the
1960s, often in a 10:1 blend with saccharin which had a
better taste than that of either sweetener alone. In 1969,
in immediate response to a study that suggested that
cyclamate might cause bladder cancer in rats, the US-
FDA announced that cyclamate would be banned; the
ban took effect in 1970. Later, extensive further studies
in rats, mice, dogs, hamsters, and monkeys did not
show any link between cyclamate and cancer. Thus, on
the basis of the complete body of evidence, scientists
have concluded that cyclamate is not carcinogenic.
The primary concern was that it could be toxic to
some individuals who appear to metabolize cyclamate
to cyclohexylamine. However, in 1982 the FDA’s
Cancer Assessment Committee concluded that it was
not carcinogenic in animal experiments and did not
present cancer risk in humans. The JECFA and SCF
gave a favourable opinion and it is utilised in more than
50 countries worldwide.
It is known that people metabolize cyclamate in
different ways. Some people excrete all or practically
all of it unchanged, while others convert variable
amounts occasionally -as much as 85% of ingested
cyclamate- into a metabolite called cyclohexylamine,
which has a far greater potential for toxicity than cycla-
mate itself. Data on the extent to which individuals
convert cyclamate to cyclohexylamine during long-
term consumption were supported by the lack of an
association between cyclamate and cyclohexylamine
and male infertility in humans. The relationship to
infertility was of interest because high doses of cyclo-
hexylamine caused testicular atrophy in rats.
Stevia/steviol glycosides
Steviol glycosides are natural sweet tasting
constituents of Stevia rebaudiana, a South American
shrub of the Chrysanthemum family that is commonly
called stevia, and contains intensely sweet substances that
are 250 to 300 times sweeter than sugar. Steviol glycoside
preparations usually contain the glycosides Stevioside
(no less 95%) and Rebaudioside A as the major compo-
nents. Stevioside was evaluated by the SCF (1999).
JECFA (2009) reviewed its safety and established an ADI
for steviol glycosides (expressed as steviol equivalents)
of 0-4 mg/kg bw/day. The EFSA ANS Panel (2010)
concluded that steviol glycosides are not carcinogenic,
genotoxic or associated with any reproductive/develop-
mental toxicity. The ANS Panel established an ADI for
steviol glycosides (expressed as steviol equivalents) of 4
mg/kg bw/day based on the application of a 100-fold
uncertainty factor (ie, this safety factor covers species
differences and sensitivity groups of the population such
as children and the elderly) to the NOAEL in the 2-year
carcinogenicity study in rats given 2.5% stevioside in the
diet (corresponding to approx. 388 mg steviol equiva-
lents/kg bw/day). Conservative estimates of steviol
glycoside exposures both in adults and in children suggest
that it is likely that the ADI would be exceeded at the
maximum proposed use levels.
Stevia has a very low acute toxicity, and no allergic
reactions to it seem to exist. However, several studies
in animals have suggested that steviol glycosides may
have adverse effects on the male reproductive system.
These studies, some of which have never been
published in English, were reviewed in detail by the
European SCF, which declined to approve stevioside
as a sweetener (SCF, 1999). Of course, the mere fact
that high doses of a substance can produce an adverse
effect in experimental animals does not necessarily
mean that the substance would be harmful when
consumed in far smaller amounts by humans.
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Low- and no-calorie sweeteners and obesity
Carmen Gómez-Candela, María Martín Fuentes, Samara Palma Milla
There are more than 1 billion adults in the world who
are overweight and at least 300 million that are clini-
cally obese. Currently the total calorie value of our diet
has increased, physical activity has declined and most
of the population is sedentary. 
The relationship between sugar and body weight is
controversial. Barclay et al demonstrated that in the
Australian population, there was a substantial decline
in refined sugar intake over the same timeframe that
obesity had increased. Mattes et al concluded that the
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current evidence does not conclusively demonstrate
that nutritive sweetened beverages have uniquely
contributed to obesity or that reducing consumption
will reduce BMI levels in general. 
Low and no calorie sweeteners (LNCS), otherwise
referred to as non nutritive sweeteners (NNS), artificial
sweeteners or non caloric sweeteners, is the term used
to describe compounds that taste sweet and provide
few or no calories, or compounds that have such an
intensely sweet taste that they can be used in food prod-
ucts at concentrations low enough to not contribute
significantly to caloric content. 
LNCS are used by adults to limit or reduce daily
energy intake and are thus a tool in weight manage-
ment. However earlier perceptions held that LNCS can
increase hunger and possibly cause weight gain. 
Although excessive and disordered eating are
factors in the development of obesity, there is no
evidence that sugars or LNCS themselves trigger
overeating. Several studies have examined the acute
effects of low calorie sweeteners on hunger and food
intake and they concluded that replacing sucrose
(sugar) with low calorie sweeteners in foods or drinks
does not increase food intake or hunger.
There is a proliferation of studies related to LNCS
consumption and weight gain. 
Kanders et al. measured weight loss, perceived feel-
ings of energy and wellbeing among 59 free-living
obese men and women. At one-year follow-up,
sustained weight loss was associated with increased
low calorie sweetener consumption, a decreased desire
for sweets and increased physical activity levels.
Kanders et al. also conducted the first large,
randomized controlled prospective outpatient clin-
ical trial investigating whether the addition of low
calorie sweeteners to a multidisciplinary weight
control programme would improve weight loss and
long-term control of body weight in 163 obese
women. The results indicated that those who
consumed low calorie sweeteners were more
successful in keeping the weight off in the long term.
Bellisle et al examined whether reducing the energy
density of sweet drinks and foods through the intro-
duction of low calorie sweeteners could be a useful
aid for weight control. Mattes and Popkin found that
longer-term trials consistently indicate that the use of
low calorie sweeteners results in slightly lower
energy intakes and that if low calorie sweeteners are
used as substitutes for higher energy-yielding sweet-
eners, they have the potential to aid in weight
management. 
In conclusion the bulk of epidemiologic studies, but
not all, reported a positive association between body
weight, weight gain and LNCS use. However, it was
noted that such findings do not prove causality. In addi-
tion, available intervention studies do not show that
LNCS use increases body weight.
In the “Workshop about LNCS, Appetite and
Weight Control”, they concluded that current knowl-
edge in this area is modest at best and does not yet
permit an informed view of how the ingestion of
energy-containing sugars and LNCS affects overall
mechanisms of energy balance and thus influences
body weight.
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Non-caloric sweeteners and dental health; review
Reina García-Closas
Dental caries and periodontal diseases constitute a
Public Health problem due to their prevalence and
socioeconomic consequences. In Spain, 36.6% of 5-6
year-old children, 45% of 12 year-old children and 92-
94% of 35-74 year-old adults have caries.
In the period 1993-2000, prevalence decreased 40%
for permanent teeth in 12 year-olds, and the ICAOD12
decreased from 4.2 in 1983 to 1.12 in 2000. In the last
10 years, caries indicators have not changed. Sixteen to
30% of Spanish adults have periodontitis. In the period
1993-2010, periodontitis decreased by half.
Dental decay results from a complex interaction
between host susceptibility, oral microflora and envi-
ronmental factors (diet, hygiene, use of fluorides). The
caries process only takes place when dental plaque
bacteria are capable of metabolising fermentable
carbohydrates into organic acids. 
The role of sugars in the etiopathogenesis of dental
caries has been established in epidemiological studies.
Sugar consumption frequency is more important than
the quantity of sugar intake. The most cariogenic sugar
is sacarose, and foods rich in processed starches and
sugars are especially cariogenic. Sugars are frequently
added to foods (pastry, snacks, cookies, breakfast
cereals, chewing-gum, milk products, sauces, bread,
processed foods, etc) and beverages. Those hidden
sugars are the main source of sugar intake in developed
countries. 
Sugar consumption has increased during the last 50
years, especially from processed foods with low
nutrient density, which contributes to dental caries and
possibly obesity. Sacarose, high-fructose corn syrup,
fructose and maltose are the most common sugars
added to foods and beverages. Non-nutritive sweet-
eners are non cariogenic since they cannot be metabo-
lized by oral bacteria. To date, of these, aspartame is
the most frequently added to non-caloric beverages,
yogurts and snacks. Saccharine, in combination with
cyclamate and/or acesulfame K- is also widespread in
beverages. Sucralose is progressively substituting
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other NCS, and the recently approved neotame is
promising. Stevia is non-cariogenic and seems to
inhibit bacterial metabolism. 
Xylitol has been widely used in chewing-gums and
candies. Clinical studies have shown that xylitol is
effective and safe as a sugar substitute for the control of
dental decay. Frequent consumption of xylitol (in
chewing-gums and candies) has shown to interfere in
bacterial growth and to reduce dental caries incidence.
Xylitol is associated with the remineralization of caries
lesions and it reduces cariogenic bacteria transmission
from mother to children in comparison to clorhexidine
and fluoride. Moreover, xylitol can prevent gingivitis
and periodontitis. The combination of xylitol and
erythritol could be specially anticariogenic. The deter-
rents of xylitol use are cost, caloric content (x0.6
energy density of sugar), and that it can be partially
fermented by intestinal bacteria, thus producing
bloating and diarrea. Other sugar alcohols (sorbitol) do
not have an important effect on plaque mass and
bacteria growth. 
In conclusion, public health policies and dietary
counselling should be oriented to reduce consumption
of foods high in refined starches and sugars and in
sugar sweetened beverages, particularly in high-risk
population groups. The substitution of sugars by non-
nutritive and non-cariogenic sweeteners (or anticario-
genic) could be an important tool in the prevention of
dental caries and should be included in preventive
programmes based on fluoride use and hygiene.
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Low-calorie sweeteners, cancer and selected other diseases;
epidemiological evidence
Carlo La Vecchia
The role of low-calorie sweeteners on cancer risk has
been widely debated since the 70s, when animal studies
found an excess bladder cancer risk in more than one
generation of rodents treated with extremely high doses
of saccharin, and a few earlier epidemiological studies
found inconsistent associations with bladder cancer risk
in humans. This was however not confirmed in subse-
quent studies, and mechanistic data showed different
saccharin metabolism in rodents and humans. To provide
information on the role of low calorie sweeteners on the
risk of cancer at several sites, we considered data from an
integrated network of case-control studies that were
conducted in Italy between 1991 and 2008. Cases were
598 incident, histologically confirmed cancers of the oral
cavity and pharynx, 304 of the oesophagus, 1,953 of the
colorectum, 460 of the larynx, 2,569 of the breast, 1,031
of the ovary, 1,294 of the prostate, and 767 of the kidney.
Controls were 7,028 patients (3,301 men and 3,727
women) admitted to the same network of general and
teaching hospitals, for acute non-neoplastic diseases. We
also considered 230 patients with cancers of the stomach
and 547 controls, 326 of the pancreas and 652 controls,
and 454 of the endometrium and 908 controls. ORs were
obtained from multiple logistic regression analyses,
including allowance for total energy, as well as major
recognized risk factors for each neoplasm. The ORs for
an increase of one sachet-day of low calorie sweeteners
were 0.81 for cancers of the oral cavity and pharynx, 1.09
for oesophagus, 0.96 for colon, 0.94 for rectum, 1.16 for
larynx, 0.94 for breast, 0.87 for ovary, 1.03 for prostate,
and 0.99 for kidney cancer. There was no material differ-
ence in risk for saccharin vs other low calorie sweet-
eners. After allowance for various confounding factors,
the ORs for ever users of sweeteners versus nonusers
were 0.80 (95% CI, 0.45-1.43) for gastric cancer, 0.62
(95% CI, 0.37-1.04) for pancreatic cancer, and 0.96
(95% CI, 0.67-1.40) for endometrial cancer. Corre-
sponding ORs for saccharin were 0.65, 0.19, and 0.71,
and for other sweeteners were 0.86, 1.16, and 1.07,
respectively. This is the first comprehensive dataset on
the relation between sweeteners, digestive tract and
selected other major cancers. Other data on brain and
haematopoietic neoplasms also showed no association.
Thus, there is now convincing epidemiologic evidence
of the absence of association between saccharin, aspar-
tame and other sweeteners, and the risk of several
common neoplasms. 
With reference to cardiovascular disease, the pooled
RR from the two studies —obtained combining the
study estimates by meta-analytic methods— was 1.19
(95% CI 0.84-1.67) for regular (≥ 1 times per day)
consumption of low-calorie beverages as compared to
non users, and 1.29 (95% CI 1.13-1.48) for regular
consumption of sugar-sweetened beverages. Available
epidemiologic data thus indicate that, while use of
sugar-sweetened beverages appears to be related to
increased risk of cardiovascular disease, consumption
of low-calorie beverages is not significantly related. 
With reference to preterm delivery, when the main
findings of the two studies were pooled, the RR was
1.25 (95% CI 1.09-1.43) for ≥ 4 servings/day of low-
calorie beverages. However, for lower levels of
consumption risk estimates were close to unity and,
most importantly, similar risk estimates were found for
sugar-sweetened beverages (RR = 1.23, 95% CI 1.06-
1.42 for ≥ 4 servings/day). Thus, the two studies, Hall-
dorsson et al., and Englund-Ogge et al, show no
evidence that low-calorie beverages have an impact on
preterm delivery at any variance from that of sugar
sweetened beverages.
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Food additives are quite an unknown topic within
the food consumption field, as well as being an issue
that consumers are deeply concerned about. Despite
the fact that they are associated to modern times,
food additives have been used for centuries. They
have been used since mankind learned how to
preserve food. Thanks to the development that food
science and technology have achieved in the past 50
years, several new substances providing some bene-
fits have been discovered, such as certain sweet-
eners used in low-calorie products, non-cariogenic
food, etc.
For the identification and control of table top sweet-
eners and those used in foodstuffs the European Union
legal framework must be taken into account, which
includes their conditions of use, specifications, autho-
rization procedure, evaluation and re-evaluation
programs. In addition the Official Control food law
must be taken in to account.
The use of additives is strongly regulated, and the
criteria used for their approval are: that there is a
reasonable technological need, that they are safe, and
that they do not mislead consumers.
All food additives must have a demonstrated
useful purpose and must undergo a rigorous and
comprehensive Scientific Assessment to assure
their safety before their use is authorized. At the
level of the European Union the risk assessment of
food additives is the responsibility of the European
Food Safety Authority (EFSA). At the international
level, the Joint Expert Committee on Food Addi-
tives (JECFA), which works under the auspices of
the United Nations Food and Agriculture Organiza-
tion (FAO) and the World Health Organization
(WHO), is responsible for the evaluation and risk
assessment of Food Additives.
One element of the legislation about additives in the
EU is the Regulation (EC) 1333/2008 that provides
harmonized lists of authorized food additives
(Annexes II and III), their conditions of use, including
the additives used in additives, enzymes and flavors, as
well as their labeling legal requirements.
The European Union defines 26 functional classes
according to the technological activity, and sweeteners
are included as one of those.
For most of the additives that are authorized there is
a minimum level necessary to achieve the desired
effect. This level takes into account the acceptable
daily intake (from the Additive and from any other
sources) and the possible daily intake even for the
most sensitive consumers. However, there is the
possibility to use additives without complying
with maximum levels and following the principle
“quantum satis”, which means the use of the
minimum amount required to obtain the desired effect.
The presence of additives in intermediate products is
also permitted.
The principle of transfer allows the presence of an
unauthorised additive in a particular food, as long as it
has been used in any of the ingredients contained in it,
or by being part of another additive, flavors and/or
enzyme.
There is a common authorization procedure applic-
able for the 28 countries of the European Union estab-
lished in the Regulation (EC) 1331/2008. There is an
application that shall be submitted by the MMSE or the
interested party to the European Commission (EC), and
the EC requests EFSA to conduct the risk assessment.
The dossier shall include the documentation required
in the regulation that is mandatory for both the risk and
management assessment.
The European Commission established a Re-evalua-
tion of Additives program for the additives approved
before 2009. The priority for re-evaluation takes into
account: exposure assessment to consumers, the
elapsed time since the last risk assessment, the avail-
ability of new scientific evidences and the level of use
of the additive. Dyes, which had old SCF assessments,
were prioritized. The evaluation of sweeteners that is
the most recent and will be revaluated at the end of the
program.
Official Control covers companies and products.
The activities included in official controls are: inspec-
tion, supervision of HACCP’s stakeholder programs,
sampling and analysis. They are undertaken by the
competent authorities at any stage of production,
processing and/or distribution. For the effectiveness of
these operations they have to comply with the provi-
sions in the Regulation (EC) 882/2004, in terms of
procedures, training of control authorities, auditing
controls, etc. 
The Community of Madrid has two programs in
place that provide the official controls described
above: «Food Inspection Program and Control and
Program Monitoring and Control of Contaminants and
Residues in Food». They aim to control companies that
process, pack, storage and / or distribute foodstuffs,
including sweeteners. 
The companies in the additives sector are considered
in the categories of A and B of lower risk given the
conformity of the official controls obtained during past
years.
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Identification and control of sweeteners in food products
Eladia Franco Vargas
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Health protection has been constant throughout
history, although it is true that all the health aspects
have centred on the concept of illness during the XIX
century and great part of the XX century. In the Inter-
national Congress on Primary Health Care of Alma-
Ata, health was defined as a state of complete physical,
social and mental well-being, and not just simply a lack
of illness. The fundamental pillars of primary care are
prevention and health promotion, as well as the way to
manage any health problem subject to being attended
to within the primary care setting.
The Portfolio of Primary Care’s Standard Services
of the Community of Madrid is defined as “the offer of
benefits and special monitoring services for the citi-
zens, prioritized depending on the health problems and
needs of the population of Madrid, that are subject to
being attended by the first level of care, and in which,
according to the standards established, have the
purpose of guaranteeing the quality of care”.
Health education is a process that approaches not
only how health information is transmitted, but also
helps to foment motivation, personal abilities and the
self-esteem necessary to adopt measures destined to
improve health.
Through the Service Portfolio and a series of peri-
odic recommendations, preventive methods are put
into action based on scientific evidence. Of all the
services that it encompasses we will refer to: Pregnant
women care, The promotion of childhood health
habits, Overweight children care, The promotion of
health in adolescence, Childhood oral hygiene and The
promotion of healthy lifestyles for adults.
There is vast evidence of the correlation between
specific health lifestyles and the decrease of the main
chronic diseases. Many interventions have been based
on the behaviourism model, suggesting different ways
of acting depending on the person’s state. This model
has limitations when it comes to complex behaviours
(physical activity or eating behaviour). International
recommendations suggest that consulting and advice
interventions be based on the 5 A’s model created by the
USTSTF. And last of all the Institute for Clinical
Systems Improvement (ICSI) advises to carry out a
personalized intervention adequate to the risk presented,
increasing the person’s awareness and motivating
him/her to change.
With the SWOT analysis we can reach the following
conclusions:
1. Training health professionals. The lack of knowl-
edge on behalf of health professionals about differ-
ential features between different sweeteners in
order to give advice and/or select a determined
sweeteners based on its properties (weakness).
2. Commitment with the Administration. There are
few solid studies based on humans that confirm
their possible benefits (weakness).
3. Patient training. The use and abuse of “evidence”
provided by the media leads to lack of informa-
tion for the patient (threat).
4. An increasing interest of the population and health
professionals in nutraceutical products with sweet-
ening properties, which could take us to the
creation of coordinated applications related to their
use and interaction with medication and/or foods
(strength).
5. A common message when it comes to preventing
chronic diseases with health promotion, the
growing culture of caring for one’s body and
achieving an optimum health state (opportunity).
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Sweeteners, nutrition and medicine; what do we do in primary care?
M.ª Luisa López Díaz-Ufano
Sweeteners and food; view of the health administration
Jesús Vázquez Castro
Each year 2.8 million adult people die of overweight
and obesity. 11% of the Spanish population is diabetic.
Between 92-94% of people aged 35 years and over
suffer from tooth decay. 
In the Community of Madrid the prevalence of obesity
in those aged 6-18 years is 7.4% and is 21.7% in adults
(30-74 years old). According to other communities the
Community of Madrid is situated at a medium-low level.
The significant observed increase in the consump-
tion of sugar sweetened beverages may contribute to
obesity. 
For these reasons, the aim of the administration in
the Autonomous Community of Madrid was to
improve the professional knowledge of Primary Care
professionals and citizens in relation to sweeteners and
food. A SWOT (Strength, Weakness, Opportunities,
Threats) analysis was administered to Primary Care
professionals in the Community of Madrid to measure
their knowledge of sweeteners. The results are shown
in table III.
In conclusion, the following recommendations can
be made:
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– The actions should improve the influence of food
and nutrition knowledge on health and cover it
throughout all of the life cycle.
– The information about the use of sweeteners should
be transmitted in diabetic education and obesity sessions.
– We should have nutritional information about
consumer products that contain sweeteners.
– It is necessary to have evidence based information
to formulate consumption recommendations.
– It is important to inform and train Primary Care
professionals on nutrition, dietetic aspects, the use of
sweeteners and the interactions of drugs with food, as
well as assuring that protocols and dietary prescrip-
tions are unified.
– The key is to have designated units that inform
professionals and citizens to encourage consumer
co-responsibility and to increase their knowledge
base.
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Table III
Sweeteners. SWOT
Weakness Threats
• Lack of robust studies in humans. • No existence of data about the use of sweeteners in the long term.
• Little information on nutrition labels of consumer products which • No knowledge of the specific amounts of dose-response. 
contain sweeteners. • Doubts about the risk of use.
Strength Opportunities
• The increased interest in these products. • The information on the nutritional label should include sweeteners.
• Beneficial effects. • It is necessary to be aware of the dose-response amount to clarify
• Sweet taste without calorie inputs. the effects of use at the metabolic level.
• They are safe if consumption corresponds to the level of daily intake • Include studies with specific pathologies (diabetes) or special 
established by regulatory agencies. groups (pregnant women or children).
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